Ibrutinib in relapsed chronic lymphocytic leukemia.

@article{Neffendorf2013IbrutinibIR,
  title={Ibrutinib in relapsed chronic lymphocytic leukemia.},
  author={James E Neffendorf and Irina I Gout and G{\"o}ran Darius Hildebrand},
  journal={The New England journal of medicine},
  year={2013},
  volume={369 13},
  pages={1277}
}
To the Editor: Byrd et al. (July 4 issue)1 describe the beneficial targeting of Bruton’s tyrosine kinase (BTK) with ibrutinib in relapsed chronic lymphocytic leukemia (CLL), and we note the absence of any visual deterioration in the cohort. We herein report on an 80-year-old woman with CLL who had received ibrutinib for the preceding 6 months and who had a 1-month history of deteriorating vision. Examination revealed a best corrected vision of 20/40 in each eye and bilateral cataracts of a very… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 64 extracted citations

Similar Papers

Loading similar papers…